New patient intro: $89 first month, then $199/month. Cancel anytime.
The Aurelius Journal
The research is public. We just make it readable.
Every compound in our protocols has a paper trail. These articles walk through the actual studies, rate the evidence honestly, and flag where the data is still being worked out. No cherry picked abstracts. No marketing language.
Tirzepatide and Fatty Liver: 10 Reasons the Liver Story Is the Quietest Big Result in the Trial Program
Tirzepatide cuts liver fat 40 to 60 percent and improves fibrosis biomarkers in MASLD and MASH. Here are 10 reasons the quiet liver result matters.
All Articles
Tirzepatide for Obstructive Sleep Apnea: 10 Reasons the SURMOUNT-OSA Result Changed the Treatment Picture
Zepbound became the first medication ever FDA approved for moderate to severe OSA in adults with obesity. Here are 10 reasons the SURMOUNT-OSA result changed treatment.
Tirzepatide and Your Lipid Panel: 10 Reasons the Triglyceride Drop Matters More Than the LDL Story
Tirzepatide drops triglycerides 15 to 30 percent, far more than its modest LDL effect. Here are 10 reasons the lipid changes matter for metabolic syndrome.
Tirzepatide and Body Composition: 10 Reasons the Scale Number Hides What Actually Changed
Tirzepatide averaged 20 to 22 percent bodyweight loss in SURMOUNT, but the composition underneath the scale, visceral fat and lean mass, decides whether it lasts.
Tirzepatide and HbA1c: 10 Reasons the Dual Agonist Produces the Largest Glycemic Drops Ever Measured
Tirzepatide lowered HbA1c 1.9 to 2.6 points in the SURPASS trials, the largest drops ever for a non insulin medication. Here are 10 reasons the magnitude matters.
Tirzepatide and PCOS: 10 Reasons a Dual GLP-1/GIP Agonist Targets the Underlying Mechanism
PCOS is a metabolic disorder of insulin resistance before it is a reproductive one. Here are 10 reasons tirzepatide targets the upstream driver, and the evidence limits.
Tirzepatide and Exercise: 10 Reasons Lifting Heavy Beats Cardio for Anyone on a GLP-1
On tirzepatide the drug already creates the deficit, so the gym's real job is protecting muscle. Here are 10 reasons lifting heavy beats cardio on a GLP-1.
What to Eat on Tirzepatide: 10 Foods That Protect Muscle and Micronutrients
Tirzepatide suppresses appetite and slows gastric emptying, which makes protein and micronutrients harder to hit. Here are 10 foods that protect lean mass and energy.
Tirzepatide and Blood Pressure: 10 Reasons the BP Drop Is Larger Than the Weight Loss Alone Explains
Systolic BP drops 6 to 10 mmHg on tirzepatide — more than weight loss alone explains. Here are 10 reasons the BP reduction matters clinically.
Tirzepatide and Heart Health: 10 Cardiovascular Benefits the Trials Have Already Quantified
Blood pressure, triglycerides, visceral fat, and HbA1c all improve measurably on tirzepatide. Here are 10 cardiovascular benefits backed by the trial data.
10 Reasons Women Over 40 Should Consider Microdose GLP-1 Before Full Dose
Why a gentler GLP-1 approach may be the smartest first step for women navigating perimenopause, hormonal shifts, and menopausal metabolic change.
10 Reasons Microdose GLP-1 Is Safer for Long-Term Use Than Standard Protocols
Published clinical data on tolerability, adherence, lean mass preservation, and why physician-supervised microdose protocols reduce long-term risk.
10 Reasons Your Brain Chemistry Changes on Microdose GLP-1
Dopamine, BDNF, neuroinflammation, slow-wave sleep — a clinician's breakdown of what microdose GLP-1 does to the nervous system across 9 brain regions.
The Side Effects of Ozempic and Why Patients Are Quietly Switching to Microdose Protocols
Ten reasons patients are switching from full-dose Ozempic to microdose GLP-1 protocols, from nausea and muscle loss to rebound weight gain.
Reversing Prediabetes in Men: DPP Data, GLP-1 Evidence, and the Path Back
The DPP showed 58 percent T2D risk reduction from 7 percent weight loss. A 12-month protocol combining lifestyle and, for eligible men, GLP-1 to normalize A1C sustainably.
A1C 5.7 to 6.4: The Ten-Year Decision and What the GLP-1 Evidence Actually Shows
An A1C between 5.7 and 6.4 percent is a ten year fork. Here is what the DPP data, ADA guidance, and GLP-1 trials actually show about moving the number.
Weight Loss After Heart Attack: What the SELECT Trial Changed for Cardiac Rehab Graduates
The SELECT trial showed semaglutide reduced cardiovascular events by 20% in post-cardiac patients with obesity. What that means for cardiac rehab graduates and how a protocol works.
TRT and GLP-1 Together: Why Testosterone Therapy Doesn't Move the Last 15 Pounds
TRT restores testosterone but rarely drives meaningful fat loss alone. The mechanism behind stubborn midsection fat on TRT and what adding GLP-1 actually changes.
Pregabalin Weight Gain: Why Lyrica Adds Pounds and What to Do Without Stopping
Pregabalin drives weight gain in 11.4% of users via appetite increase and edema. The mechanism, the tradeoffs, and what works when the neuropathy medication cannot be stopped.
Surgical Menopause Weight Gain: Why It Happens Faster and What Is Different
After BSO, weight accumulates up to 3x faster than natural menopause. The biology of abrupt estrogen loss, visceral fat preference, and what a weight protocol for this population should address.
Metoprolol Weight Gain in Men: The Mechanism and What to Do About It
Metoprolol can drive 2 to 5 kg per year of weight gain in roughly 26 percent of long term users. The mechanism, the trade offs, and a coordinated weight plan that runs alongside cardiac protection.
Beta Blockers and GLP-1: Can You Take Them Together? A Drug Interaction Guide
Beta blockers and GLP-1 medications can be taken together with specific coordination. The interaction profile, bradycardia and hypoglycemia risks, and how providers structure the protocol.
How Microdosing GLP-1 Differs from Standard Weight Loss Doses
Microdosing and standard dosing are different tools built around different goals. The evidence base is younger for microdosing but the clinical logic is coherent.
What the Latest GLP-1 Research Is Telling Us This Month
Three April 2026 studies on GLP-1 resistance, genetic side effect predictors, and benefits beyond weight loss are reshaping how clinicians think about protocols.
GLP-1 and Testosterone: What the 53% Increase Means for Men Who Optimize
A 2026 meta-analysis confirms GLP-1 receptor agonists significantly raise testosterone in men. Here is what the data shows and why the optimization community is paying attention.
GLP-1 and Sleep: How Receptor Activation Changes Your Sleep Architecture
GLP-1 receptors in the dorsomedial hypothalamus directly regulate circadian biology. Here is what the research shows about sleep quality, beyond the sleep apnea headlines.
GLP-1 and Muscle Loss: How to Preserve Lean Mass While Running a Protocol
At full therapeutic doses, 25–40% of weight lost on GLP-1s can come from lean tissue. Here is the evidence based protocol for lean mass preservation.
GLP-1 and Heart Health: What the SELECT Trial Data Means If You're Not Overweight
The SELECT trial found a 20% reduction in cardiovascular events on semaglutide, partially independent of weight loss. Here is what the cardiac mechanism means for non-obese users.
GLP-1 and Alcohol Cravings: The Neuroscience Behind Why Drinking Habits Change
GLP-1 receptors in the brain's reward circuit directly modulate dopamine signaling. Here is the neuroscience behind why alcohol cravings change on a GLP-1 protocol.
GLP-1 and Brain Fog: The Biology Behind Cognitive Symptoms and What Addresses Them
Brain fog is not vague — it has a documented biology. Here is what GLP-1 receptors in the hippocampus and cortex do to neuroinflammation, insulin signaling, and cognitive function.
GLP-1 and Insulin Sensitivity: What Microdosing Does for Metabolism
Normal A1C does not mean optimal metabolism. Here is what GLP-1 receptor activation does to insulin sensitivity and glucose variability in people without diabetes.
GLP-1 and Longevity: What the Research Actually Shows (And Why Biohackers Are Paying Attention)
Researchers are now calling GLP-1s the first longevity drugs. Here is what the science actually shows about aging, healthspan, and why the biohacking community is paying attention.
Oral vs. Injectable GLP-1: What Women Need to Know Before Starting a Protocol
Injectable GLP-1 was built for clinical weight loss. Oral microdosed protocols use the same receptor mechanism at a fraction of the dose, with fewer side effects and no needle.
Microdosing semaglutide vs. the full dose: what is actually different?
Full-dose GLP-1 protocols were designed for T2D. The metabolic levers they pull are real. The side effect profile at therapeutic doses is also real. Here's what changes at a fraction of that dose.
GLP-1 for perimenopause: why women are choosing microdosed oral protocols over injections
Perimenopause isn't primarily a weight problem. It's a metabolic, hormonal, and neurological shift. Here's how microdosed oral GLP-1 addresses the mechanisms behind energy crashes, brain fog, and sleep disruption — without a needle.